Answers are grounded in this paper and cite their sources.
Currently, sickle cell anemia is a β-hemoglobinopathy, meaning a genetic autosomal recessive disease, affecting 400,000 newborns worldwide. Approximately 5% of the global population are carriers of genes causing this pathology. Regarding treatment, there are medical and pharmacological therapies for the disease; however, the only known curative option is allogeneic hematopoietic stem cell transplantation. Nonetheless, there is a high rejection rate, compounded by the fact that it is only available to a limited number of patients. Now, there is a new alternative: gene therapy, which is based on the addition and modification of genes.
No takes yet. Share an insight, caveat, or question.
Vázquez et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: